Financial mission

How onco.fit makes money

onco.fit builds a financially sustainable cancer-navigation platform without making a patient's confusion, vulnerability or clinical risk the product. Essential cancer-suspicion navigation stays free or affordable. Revenue comes primarily from institutions that benefit when patients reach appropriate care earlier, complete the right diagnostic pathway, avoid unnecessary spend, and stay connected to coordinated care.

Payment never changes your care.Payment, sponsorship, or ability to pay never changes a patient's clinical urgency or pathway recommendations. No investor, hospital, diagnostic, pharma, or other payer may purchase influence over patient-specific guidance.
For patients

Free where access and trust require it

Essential navigation stays ₹0 for the patient, always. Optional higher-touch services may be paid, but they never change clinical urgency or pathway.

Always free

₹0essential
  • Essential cancer-suspicion navigation
  • Diagnostic Necessity Check (what a test changes before you pay)
  • Government scheme and support matching
  • Questions to ask your doctor, and a referral packet
  • Emergency / red-flag routing to urgent care

Optional, paid

+higher touch
  • A dedicated human navigator
  • Second-opinion coordination
  • Document organization
  • Appointment support
  • Treatment-centre comparison
  • Financial and insurance navigation
Who pays, and for what

Institutions pay for measurable value

The user and the payer are often different. A patient uses onco.fit while a hospital, employer, insurer, government programme or funder sponsors it, for coordination and outcomes, never for influence over guidance.

We are the map, not another destination.onco.fit will not compete with hospitals or specialty clinic networks to own cancer care. It provides the trusted navigation and coordination infrastructure that enables patients to access the most appropriate care across public, charitable and private providers.

Hospitals & cancer networks

Pay for referral quality, patient preparation, diagnostic completion, attendance, continuity, and drop-off visibility. Infrastructure and workflow, not guaranteed referrals.

Employers & benefit platforms

Sponsor navigation for their people so essential guidance stays free to the patient.

Insurers & TPAs

Sponsor coordinated pathways and pathway completion.

Government health programmes

Subsidize equitable access to essential navigation.

CSR & philanthropy

Fund free access, education, and equity, without influence over guidance.

Diagnostic networks

Pay for workflow only (scheduling, report retrieval, pathway completion). Never more when more or costlier tests are ordered.

Pharma (strict governance)

May support education, navigation, research or diagnostic access only. May not influence patient-specific guidance, treatment choices, or pathway logic.

Patients (optional premium)

May pay for optional higher-touch services. Ability to pay does not determine clinical urgency.

What we refuse

Models onco.fit will not use

  • Commissions linked to hospital bills or treatment value
  • Payments based on diagnostic-test volume or cost
  • Paid rankings of doctors or hospitals
  • Undisclosed sale of patient leads
  • Sale of identifiable patient data
  • Sponsored clinical recommendations
  • Pharma-controlled pathways
  • Mandatory patient subscriptions for essential navigation

Are we paid because care is better coordinated, or because more healthcare is being sold? We pursue the first and refuse the second.

Honest outcomes

What we measure, and what we do not claim

We measure

  • Completed referrals
  • Time to the appropriate consultation
  • Diagnostic-pathway completion
  • Reduced loss to follow-up
  • Improved referral quality
  • Successful access to benefits or financial support
  • Reduced duplicate testing where measurable

We do not claim (yet)

  • Improved survival
  • Reduced mortality
  • Lower total treatment cost

Not until there is sufficient evidence.

Free where access and trust require it, paid where institutions receive measurable value, and independently governed wherever commercial incentives could influence care.

A model a patient can trust.

Free where it must be, paid where institutions receive measurable value, independently governed wherever incentives could touch care.